Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Pertuzumab plus trastuzumab in metastatic breast cancer.

Şendur MA, Aksoy S, Zengin N.

N Engl J Med. 2012 Apr 5;366(14):1348; author reply 1349-50. doi: 10.1056/NEJMc1201462#SA1. No abstract available.

PMID:
22475602
2.

Pertuzumab plus trastuzumab in metastatic breast cancer.

Revannasiddaiah S, Seam R, Gupta M.

N Engl J Med. 2012 Apr 5;366(14):1349; author reply 1349-50. doi: 10.1056/NEJMc1201462#SA3. No abstract available.

PMID:
22475604
3.

Pertuzumab plus trastuzumab in metastatic breast cancer.

Li-Wan-Po A.

N Engl J Med. 2012 Apr 5;366(14):1348-9; author reply 1349-50. doi: 10.1056/NEJMc1201462#SA2. No abstract available.

PMID:
22475603
4.

Pertuzumab (Perjecta) for HER2-positive metastatic breast cancer.

[No authors listed]

Med Lett Drugs Ther. 2012 Jul 23;54(1395):59-60. No abstract available.

PMID:
22825690
5.

Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.

Kawajiri H, Takashima T, Kashiwagi S, Noda S, Onoda N, Hirakawa K.

Expert Rev Anticancer Ther. 2015 Jan;15(1):17-26. doi: 10.1586/14737140.2015.992418. Epub 2014 Dec 12. Review.

PMID:
25494663
6.

HER2 therapy--an abundance of riches.

Gradishar WJ.

N Engl J Med. 2012 Jan 12;366(2):176-8. doi: 10.1056/NEJMe1113641. Epub 2011 Dec 7. No abstract available.

PMID:
22149874
7.

Dual HER2 blockade slows metastatic breast cancer.

Bender E.

Cancer Discov. 2012 Jan;2(1):OF4. doi: 10.1158/2159-8290.CD-ND121511OL-12. Epub 2011 Dec 15. No abstract available.

8.

[Pertuzumab+trastuzumab+DTX therapy].

Maejima A, Tamura K.

Nihon Rinsho. 2015 Feb;73 Suppl 2:553-7. Japanese. No abstract available.

PMID:
25831821
9.

Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancer.

Smith MB, Reardon J, Olson EM.

Drugs Today (Barc). 2012 Nov;48(11):713-22. doi: 10.1358/dot.2012.48.11.1885879. Review.

10.

CLEOPATRA holds strong in final analysis.

[No authors listed]

Cancer Discov. 2014 Dec;4(12):OF3. doi: 10.1158/2159-8290.CD-NB2014-157. Epub 2014 Oct 16.

11.

Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer.

Gullo G, Zuradelli M, Sclafani F, Santoro A, Crown J.

Ann Oncol. 2012 Aug;23(8):2204-5. doi: 10.1093/annonc/mds221. Epub 2012 Jul 5. No abstract available.

12.

Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.

Swain SM, Ewer MS, Cortés J, Amadori D, Miles D, Knott A, Clark E, Benyunes MC, Ross G, Baselga J.

Oncologist. 2013;18(3):257-64. doi: 10.1634/theoncologist.2012-0448. Epub 2013 Mar 8.

13.

Exposure-response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters.

Garg A, Li J, Clark E, Knott A, Carrothers TJ, Marier JF, Cortés J, Brewster M, Visich J, Lum B.

Cancer Chemother Pharmacol. 2013 Nov;72(5):1133-41. doi: 10.1007/s00280-013-2279-6. Epub 2013 Sep 3.

14.

Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel.

Cortés J, Swain SM, Kudaba I, Hauschild M, Patel T, Grincuka E, Masuda N, McNally V, Ross G, Brewster M, Marier JF, Trinh MM, Garg A, Nijem I, Visich J, Lum BL, Baselga J.

Anticancer Drugs. 2013 Nov;24(10):1084-92. doi: 10.1097/CAD.0000000000000016.

PMID:
23969513
15.

The beautiful history of pertuzumab.

Perez-Garcia J, Muñoz-Couselo E, Ortega V, Cortes J.

Expert Rev Anticancer Ther. 2012 Jun;12(6):703-5. doi: 10.1586/era.12.46. No abstract available.

PMID:
22716485
16.

Pertuzumab (Perjeta) for preoperative use in HER2-positive breast cancer.

[No authors listed]

Med Lett Drugs Ther. 2013 Dec 9;55(1431):98-9. No abstract available.

PMID:
24322664
17.

The clinical utility of HER2-targeted therapy in the neoadjuvant setting: recent results from the San Antonio Breast Cancer Symposium.

Abair T, O'Shaughnessy J.

Clin Breast Cancer. 2011 Feb;11(1):15-9. doi: 10.3816/CBC.2011.n.003. No abstract available.

PMID:
21989832
18.

[Combination therapy herceptin+taxotere/Herceptin+navelbine].

Meden H.

Onkologie. 2002 Dec;25 Suppl 5:15-6. German. No abstract available.

PMID:
23573614
19.

HER2 testing in patients with breast cancer.

Dixon JM, Wilson V, Verrill M, Symmans WF.

BMJ. 2012 Jun 11;344:e3958. doi: 10.1136/bmj.e3958. No abstract available.

PMID:
22689887
20.

Bevacizumab in neoadjuvant treatment for breast cancer.

Miklos GL.

N Engl J Med. 2012 Apr 26;366(17):1638; author reply 1639-40. doi: 10.1056/NEJMc1202229#SA3. No abstract available.

PMID:
22533583
Items per page

Supplemental Content

Write to the Help Desk